Hookipa Pharma Says It Will Present Preclinical Data Related To The HB-700 Program For The Treatment Of KRAS Mutated Cancers
Hookipa Pharma Says It Will Present Preclinical Data Related To The HB-700 Program For The Treatment Of KRAS Mutated Cancers
hookipa pharma表示將展示與治療KRAS突變癌症有關的Hb-700計劃的臨床前數據
Hookipa Pharma Says It Will Present Preclinical Data Related To The HB-700 Program For The Treatment Of KRAS Mutated Cancers
hookipa pharma表示將展示與治療KRAS突變癌症有關的Hb-700計劃的臨床前數據
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間